US.A · Agilent Technologies

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.968025751072961,
        "turnoverUsdM": 178.972659,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.A",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 131.5014,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 5.9,
      "take_profit_price": 150.0488,
      "target_multiplier": 1.9,
      "technical_strength": 1.95,
      "take_profit_percent": 7.3
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2297736967681296,
    "stopLossPercent": 5.936051502145922,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 72.4,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 65.4,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 135.505,
    "ma50": 132.2014,
    "close": 139.8,
    "prevClose": 138.37,
    "avgVolume20": 2174879,
    "volumeRatio": 0.59,
    "changePercent": 1.03
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.01385162085720526,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 0.5790519786452688,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.8668912199094578,
      "volat_points": 0,
      "day_range_pct": 0.023175965665236116,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 72.4,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 72,
        "contribution": 3.6
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 10,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 66.67,
        "contribution": 10
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 6.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 66,
        "contribution": 6.6
      },
      {
        "raw": 20,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 66.67,
        "contribution": 20
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 65.4,
    "details": [
      "基本面分析總分: 3.6/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 10/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 6.6/10分",
      "技術信號分析總分: 20/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 3.6,
      "資金流": 13.2,
      "市場環境": 10,
      "情緒分析": 6,
      "技術信號": 20,
      "風險管理": 6.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.6,
          "turnoverUsdM": 178.972659,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 1.6,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.A",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3,
            "details": {
              "qqq": {
                "ma20": 699.88099675,
                "ma50": 714.8264005399999,
                "name": "QQQ",
                "close": 700.070007,
                "points": 1
              },
              "spy": {
                "ma20": 746.0140036500002,
                "ma50": 745.31840316,
                "name": "SPY",
                "close": 757.66998,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.968025751072961,
          "atrPoints": 3,
          "cciPoints": 4,
          "vixPoints": 0,
          "marketTrendPoints": 3
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141102982,
                "url": "https://finnhub.io/api/news?id=62f293addd73b6ee2ad4dc43b9605aa74a4574f62a6382348c776bea83676b65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Agilent Technologies Inc. (NYSE:A) just extended its diagnostics franchise into one of oncology’s toughest corners. On July 23, the company said European regulators had certified its PD-L1 IHC 22C3 pharmDx test, Code SK006, as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma. That lets pathologists flag patients who might benefit from […]",
                "category": "company",
                "datetime": 1785791727,
                "headline": "Agilent Technologies (A) Expands Its Oncology Diagnostics Reach—Can Growth Keep Up?"
              },
              {
                "id": 141103171,
                "url": "https://finnhub.io/api/news?id=2dd88a54341cf14e6baa4cffeea6d4819a7bc50413f219d15c0c28b9d506a609",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "COR's Q3 results could reflect specialty pharma strength, oncology expansion and margin gains, even as pricing dynamics and GLP-1 trends pressure revenues.",
                "category": "company",
                "datetime": 1785783420,
                "headline": "Cencora to Report Q3 Earnings: Is a Beat Likely for the Stock?"
              },
              {
                "id": 141045284,
                "url": "https://finnhub.io/api/news?id=e230c03b4e1344ce98d6715be8d70854b2f51144a5c95c8a41454206af666ffb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Precision Diagnostics And Medicine Market size & share revenue was valued at approximately USD 147.23 Billion in 2025 and is expected to reach USD 159.66 Billion in 2026 and is expected to reach around USD 345.75 Billion by 2035, at a CAGR of 8.91% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are F. Hoff",
                "category": "company",
                "datetime": 1785259800,
                "headline": "[Latest] Global Precision Diagnostics And Medicine Market Size/Share Worth USD 345.75 Billion by 2035 at a 8.91% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)"
              },
              {
                "id": 141019431,
                "url": "https://finnhub.io/api/news?id=18c7b326214a62c9e3f90e044852248d05757ac5391a1fbb9d4c227685f888f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Agilent Technologies (A) has drawn fresh attention after receiving U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic for several OPDIVO based cancer treatments. See our latest analysis for Agilent Technologies. Agilent Technologies' recent FDA approval arrives as the stock trades at $138.57, with a 90 day share price return of 19.92% and a 1 year total shareholder return of 16.23%, indicating that momentum has strengthened in recent...",
                "category": "company",
                "datetime": 1785014182,
                "headline": "Is Agilent Technologies (A) Undervalued Following Its FDA Approval For OPDIVO Companion Diagnostics?"
              },
              {
                "id": 141016927,
                "url": "https://finnhub.io/api/news?id=b6cbad09d7c61cc4a78f2c28f2ef0d800d1508f9977fbf1f232e42e0808a3ecc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "In July 2026, Agilent Technologies received U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with several gastric and esophageal cancers who may be eligible for treatment with Bristol Myers Squibb’s OPDIVO and OPDIVO QVANTIG, for use exclusively on the Agilent Autostainer Link 48 platform. This approval deepens Agilent’s role in immuno-oncology testing by tying its assay directly to widely used PD-1 therapies in...",
                "category": "company",
                "datetime": 1784992370,
                "headline": "Why Agilent Technologies (A) Is Up 5.4% After New FDA Nod For OPDIVO Cancer Test"
              },
              {
                "id": 140907179,
                "url": "https://finnhub.io/api/news?id=340495186adc8c7a39222547fca20d68d8e33abc9353106904ef2fa4f9f6d435",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "A",
                "summary": "Agilent Technologies (A) shows a strong technical breakout setup with an 8/10 Technical Rating and 9/10 Setup Quality, combining a solid uptrend with a tight consolidation near a resistance zone for a potential energetic move.",
                "category": "company",
                "datetime": 1784113828,
                "headline": "Agilent Technologies (NYSE:A) Shows Strong Breakout Setup with Top-Tier Technical Ratings"
              },
              {
                "id": 140891351,
                "url": "https://finnhub.io/api/news?id=e241c1ffe64c739ef93aa279e16d8b927df3ed6bdc10741dd02d51309b8e4eef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "If you’re an Alamar Biosciences (ALMR) shareholder, Friday was a good day. The stock climbed +7.3%, closing the session at a new 52-week high of $28.42. That’s a tidy gain on a day when the S&P 500 barely nudged up +0.4% and some key industry peers actually lost ground.",
                "category": "company",
                "datetime": 1783975817,
                "headline": "Alamar Hits A High Note On Alzheimer's Buzz"
              },
              {
                "id": 140891435,
                "url": "https://finnhub.io/api/news?id=b2c25386d7c3ec7bdeefe1aa97da53868cf1b24991f81ccde9342c2c6f03d2f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Over the past six months, Agilent’s stock price fell to $134.31. Shareholders have lost 8.2% of their capital, which is disappointing considering the S&P 500 has climbed by 8.4%. This may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1783975599,
                "headline": "Agilent (A): Buy, Sell, or Hold Post Q1 Earnings?"
              }
            ],
            "raw_source": [
              {
                "id": 141102982,
                "url": "https://finnhub.io/api/news?id=62f293addd73b6ee2ad4dc43b9605aa74a4574f62a6382348c776bea83676b65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Agilent Technologies Inc. (NYSE:A) just extended its diagnostics franchise into one of oncology’s toughest corners. On July 23, the company said European regulators had certified its PD-L1 IHC 22C3 pharmDx test, Code SK006, as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma. That lets pathologists flag patients who might benefit from […]",
                "category": "company",
                "datetime": 1785791727,
                "headline": "Agilent Technologies (A) Expands Its Oncology Diagnostics Reach—Can Growth Keep Up?"
              },
              {
                "id": 141103171,
                "url": "https://finnhub.io/api/news?id=2dd88a54341cf14e6baa4cffeea6d4819a7bc50413f219d15c0c28b9d506a609",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "COR's Q3 results could reflect specialty pharma strength, oncology expansion and margin gains, even as pricing dynamics and GLP-1 trends pressure revenues.",
                "category": "company",
                "datetime": 1785783420,
                "headline": "Cencora to Report Q3 Earnings: Is a Beat Likely for the Stock?"
              },
              {
                "id": 141101106,
                "url": "https://finnhub.io/api/news?id=5abe8d9ae172747fe7022fcdf4b95538561fe7641d2aa18259c89c9f3cac727a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "SOLV's Q2 results are likely to benefit from segment strength, Acera gains and cost savings, offset by tariffs and ERP-related sales timing shifts.",
                "category": "company",
                "datetime": 1785774960,
                "headline": "Solventum to Report Q2 Earnings: What's in Store for the Stock?"
              },
              {
                "id": 141100874,
                "url": "https://finnhub.io/api/news?id=6b8be8e80249eee81328fe41d0208e0f2a4ceb16bcae0bb5c93ebaec58590848",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "TMO lifted its 2026 outlook after Q2 topped estimates, driven by stronger demand, acquisitions and margin gains. Can the momentum continue?",
                "category": "company",
                "datetime": 1785771420,
                "headline": "Thermo Fisher Raises 2026 Outlook After Strong Second-Quarter Results"
              },
              {
                "id": 141102053,
                "url": "https://finnhub.io/api/news?id=67586e144f5eb86102cb965608c9bb05a1db438c2eac3a013ba54efebedaaf46",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "A",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1785764116,
                "headline": "6 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141079032,
                "url": "https://finnhub.io/api/news?id=37bec1425901ed97eb3b150eccb768342ed1b73f825ab5e848b348b44ed865c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "TMO is expanding bioproduction, AI tools and clinical data capabilities, but execution will be key as competition intensifies.",
                "category": "company",
                "datetime": 1785504000,
                "headline": "How Thermo Fisher Is Riding Bioproduction and AI-Led Growth Trends"
              },
              {
                "id": 141072967,
                "url": "https://finnhub.io/api/news?id=b87882a1733a32a94b94a807ef31827915068c20b41d6dc80024bd57afa87e23",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Stryker (SYK) delivered earnings and revenue surprises of +6.65% and +0.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785446704,
                "headline": "Stryker (SYK) Q2 Earnings and Revenues Beat Estimates"
              },
              {
                "id": 141069816,
                "url": "https://finnhub.io/api/news?id=26ef73af2e2d9dd54774b6b3923a4378abfc275210430118f5aef2cae852bbf6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Organic revenue still fell, yet a segment returning to growth and a raised outlook were enough to reprice the stock in a single session.",
                "category": "company",
                "datetime": 1785436199,
                "headline": "Avantor Stock Surged Because One Segment Stopped Shrinking"
              },
              {
                "id": 141068474,
                "url": "https://finnhub.io/api/news?id=0597a13729b6d9787ac42ddd83e5f452f49594e62235d6bb08b83ff253b36bb8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "RVTY heads into Q2 earnings with improving Life Sciences demand and resilient Diagnostics. Can stronger margins offset lingering headwinds?",
                "category": "company",
                "datetime": 1785429600,
                "headline": "Revvity to Report Q2 Earnings: What's in Store for the Stock?"
              },
              {
                "id": 141057208,
                "url": "https://finnhub.io/api/news?id=f832cb2da11893d07a5db0247094f198c3a5e1a1736dda374ef7d57abb4c0b97",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "PHG lifts its 2026 profit and free cash flow outlook after Q2 earnings increase on higher sales, productivity gains and a U.S. tariff refund benefit.",
                "category": "company",
                "datetime": 1785348060,
                "headline": "Philips Q2 Earnings and Revenues Increase Year over Year, Shares Down"
              },
              {
                "id": 141054394,
                "url": "https://finnhub.io/api/news?id=c62d6994ccc3873e4115336fb4a7b2eb4ce84aae456df23976ff7eea6e951e1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Here is how argenex SE (ARGX) and Agilent Technologies (A) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1785332403,
                "headline": "Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?"
              },
              {
                "id": 141053234,
                "url": "https://finnhub.io/api/news?id=34fdba13cf41bb17e6c91318f83b786c516a66642f1e1ec6f15be5ddd3850abc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "SANTA CLARA, Calif., July 29, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health research",
                "category": "company",
                "datetime": 1785326400,
                "headline": "Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo"
              },
              {
                "id": 141047528,
                "url": "https://finnhub.io/api/news?id=9e18301559d6e07e3d964b5cb694cef7ccf1cb3e1c5dd8fe10ba80b1ca4e9527",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "SANTA CLARA, Calif., July 28, 2026--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day.",
                "category": "company",
                "datetime": 1785269700,
                "headline": "Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26"
              },
              {
                "id": 141045284,
                "url": "https://finnhub.io/api/news?id=e230c03b4e1344ce98d6715be8d70854b2f51144a5c95c8a41454206af666ffb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Precision Diagnostics And Medicine Market size & share revenue was valued at approximately USD 147.23 Billion in 2025 and is expected to reach USD 159.66 Billion in 2026 and is expected to reach around USD 345.75 Billion by 2035, at a CAGR of 8.91% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are F. Hoff",
                "category": "company",
                "datetime": 1785259800,
                "headline": "[Latest] Global Precision Diagnostics And Medicine Market Size/Share Worth USD 345.75 Billion by 2035 at a 8.91% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)"
              },
              {
                "id": 141033952,
                "url": "https://finnhub.io/api/news?id=e1356cc922d24b2065e4fc35f5b4985c2626ea5c847c8e830a021f485c0ba596",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "SYK heads into Q2 with robotic surgery momentum, deferred revenue recovery and strong procedure demand as investors watch for earnings and margin trends.",
                "category": "company",
                "datetime": 1785157260,
                "headline": "Stryker's Q2 Results Likely to Reflect Recovery of Q1 Deferred Orders"
              },
              {
                "id": 141034153,
                "url": "https://finnhub.io/api/news?id=532c7af3118765071404809a553b30f6930cf4ea41667acd78881b6672af0c67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "DXCM's Q2 results may reflect strong G7 15 Day adoption, broader reimbursement, and expanding CGM demand as investors watch for continued double-digit revenue growth.",
                "category": "company",
                "datetime": 1785157200,
                "headline": "DXCM Q2 Results Likely to Reflect Strong G7 & Reimbursement Expansion"
              },
              {
                "id": 141019431,
                "url": "https://finnhub.io/api/news?id=18c7b326214a62c9e3f90e044852248d05757ac5391a1fbb9d4c227685f888f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Agilent Technologies (A) has drawn fresh attention after receiving U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic for several OPDIVO based cancer treatments. See our latest analysis for Agilent Technologies. Agilent Technologies' recent FDA approval arrives as the stock trades at $138.57, with a 90 day share price return of 19.92% and a 1 year total shareholder return of 16.23%, indicating that momentum has strengthened in recent...",
                "category": "company",
                "datetime": 1785014182,
                "headline": "Is Agilent Technologies (A) Undervalued Following Its FDA Approval For OPDIVO Companion Diagnostics?"
              },
              {
                "id": 141016927,
                "url": "https://finnhub.io/api/news?id=b6cbad09d7c61cc4a78f2c28f2ef0d800d1508f9977fbf1f232e42e0808a3ecc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "In July 2026, Agilent Technologies received U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with several gastric and esophageal cancers who may be eligible for treatment with Bristol Myers Squibb’s OPDIVO and OPDIVO QVANTIG, for use exclusively on the Agilent Autostainer Link 48 platform. This approval deepens Agilent’s role in immuno-oncology testing by tying its assay directly to widely used PD-1 therapies in...",
                "category": "company",
                "datetime": 1784992370,
                "headline": "Why Agilent Technologies (A) Is Up 5.4% After New FDA Nod For OPDIVO Cancer Test"
              },
              {
                "id": 141010897,
                "url": "https://finnhub.io/api/news?id=a714642a94168a011853432bdc2001ecb2ab9c54c0a4a54403aff7e73efd104d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Agilent Technologies is poised to release its third-quarter results soon, and analysts are projecting a single-digit earnings rise.",
                "category": "company",
                "datetime": 1784907558,
                "headline": "What to Expect From Agilent Technologies' Q3 2026 Earnings Report"
              },
              {
                "id": 141008022,
                "url": "https://finnhub.io/api/news?id=11f0b2223c504f705e7758c211d6947530f534883151cb699142f88e69716261",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "GE HealthCare heads into Q2 earnings season with solid revenue drivers, but inflation and tariff costs may keep margins under pressure before an expected second-half recovery.",
                "category": "company",
                "datetime": 1784906640,
                "headline": "Can GE HealthCare Sustain Growth in Q2 Amid Persistent Cost Headwinds?"
              },
              {
                "id": 141008023,
                "url": "https://finnhub.io/api/news?id=f8f30bf84e1e15f6f6e57395b4c780f642075ee558f77c259033ceff89883108",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "BAX's second-quarter results may reflect pressured earnings and sales as manufacturing inefficiencies, inflation, and product holds offset steady demand across segments.",
                "category": "company",
                "datetime": 1784906460,
                "headline": "Will Baxter's Q2 Results Continue to Reflect Operational Headwinds?"
              },
              {
                "id": 141005316,
                "url": "https://finnhub.io/api/news?id=661292b3a7ec96a6d2a8a28478195c2f9bdf03308066d137cd53ab297ad615dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 9.7% over the past six months, topping the S&P 500 by 1.8 percentage points.",
                "category": "company",
                "datetime": 1784897348,
                "headline": "1 Healthcare Stock to Research Further and 2 We Avoid"
              },
              {
                "id": 141005352,
                "url": "https://finnhub.io/api/news?id=4d73431f2c3617f58fa67a24b0853a1ef831c63ec81636bc814893cef053e08a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.",
                "category": "company",
                "datetime": 1784895812,
                "headline": "Reading Between The Lines Of DHR's Latest Call"
              },
              {
                "id": 141001846,
                "url": "https://finnhub.io/api/news?id=5d5dad4dc014209d8be9ce31f7105651a25ef2417957303c1c2d2f960ee3d2c8",
                "image": "",
                "source": "SeekingAlpha",
                "related": "A",
                "summary": "",
                "category": "company",
                "datetime": 1784845538,
                "headline": "Lithium Miners News For The Month Of July 2026"
              },
              {
                "id": 140994691,
                "url": "https://finnhub.io/api/news?id=7e710b46240704d0856571ac4bd9402c25d758a8f076a5178cab331d2433d515",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Featuring Thermo Fisher Scientific, Agilent Technologies, Merck, Eurofins Scientific, Charles River Labs and Other Key Players In Vitro Toxicology Testing Market In Vitro Toxicology Testing Market Dublin, July 23, 2026 (GLOBE NEWSWIRE) -- The \"In Vitro Toxicology Testing Market by Product, Toxicity Endpoints & Type, Technology, Method, Service, Region, Competition - Global Forecast to 2031\" has been added to ResearchAndMarkets.com's offering. The global in vitro toxicology testing market is proj",
                "category": "company",
                "datetime": 1784815740,
                "headline": "In Vitro Toxicology Testing Market to Exceed $20.97 Billion by 2031 as Non-Animal Testing & AI Adoption Accelerate - Analysis by Product, Toxicity Endpoints & Type, Technology, Method, Service, Region"
              },
              {
                "id": 140993381,
                "url": "https://finnhub.io/api/news?id=0a79cf45d524cc37a24e2553289794098bae876b5bf1de5b3ba22e031efe59f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "SANTA CLARA, Calif., July 23, 2026--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy.",
                "category": "company",
                "datetime": 1784808000,
                "headline": "Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma"
              },
              {
                "id": 140995316,
                "url": "https://finnhub.io/api/news?id=bc80a72205478fe9e3aef610d8940a9678348ad0b3298a650fd408bb17bf8800",
                "image": "",
                "source": "Benzinga",
                "related": "A",
                "summary": "102.76 +0.14 [+0.14%] ",
                "category": "company",
                "datetime": 1784802844,
                "headline": "Agilent Technologies shares are trading higher after the company announced it has received EU certification for PD-L1 IHC 22C3 pharmDx, in identifying epithelial ovarian, fallopian tube, or primary peritoneal carcinoma."
              },
              {
                "id": 140995317,
                "url": "https://finnhub.io/api/news?id=51b5cf53a9133fa81cdd196ec1adae450d010c3f753db597242d15bf6ed22701",
                "image": "",
                "source": "Benzinga",
                "related": "A",
                "summary": "Agilent Technologies Inc. (NYSE:A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with",
                "category": "company",
                "datetime": 1784793845,
                "headline": "Agilent Technologies Receives EU Certification For Code SK006 As Companion Diagnostic To Aid In Identifying Patients With Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Carcinoma"
              },
              {
                "id": 140969915,
                "url": "https://finnhub.io/api/news?id=aa72a66fb0d5bcf6c69aa9f3f299297ef27ee139d66ed757cdf8742165005e2a",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "A",
                "summary": "Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics.",
                "category": "company",
                "datetime": 1784637300,
                "headline": "Get insights into the top movers in the S&P500 index of Tuesday's pre-market session."
              },
              {
                "id": 140957691,
                "url": "https://finnhub.io/api/news?id=3c6550e2c0800b60983455c135aeac81bcdf03b6df0b0290dada176b889299dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "NOTTINGHAM, England, July 20, 2026--Multimillion dollar investment round to enable HALO to complete regulatory approval of its advanced security screening technology",
                "category": "company",
                "datetime": 1784531460,
                "headline": "Agilent Increases Its Investment in HALO X-ray Technologies"
              },
              {
                "id": 140940379,
                "url": "https://finnhub.io/api/news?id=313b6b852fad87101bd818b159b0149e5266b64044b5717f092ff2ac4d12ad63",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "A",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read here for an analysis.",
                "category": "company",
                "datetime": 1784329960,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 19"
              },
              {
                "id": 140930814,
                "url": "https://finnhub.io/api/news?id=d3dc1c2d69ab4e39d8aae41aa150cf946d1a48da7f86ea954cc9ed3844b19c84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Asia-Pacific will be the fastest-growing region. Key players include Roche, Thermo Fisher, Illumina, Agilent Technologies, and QIAGEN. Cancer Biomarkers Market Cancer Biomarkers Market Dublin, July 17, 2026 (GLOBE NEWSWIRE) -- The \"Cancer Biomarkers Market by Profiling Technology, Cancer, Product, Application, End User, And Region - Global Forecast to 2032\" has been added to ResearchAndMarkets.com's offering. Global market forecast indicates an 11.6% CAGR, with diagnostic laboratories holding th",
                "category": "company",
                "datetime": 1784285040,
                "headline": "Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate"
              },
              {
                "id": 140908427,
                "url": "https://finnhub.io/api/news?id=87096e97df6ec0e551b5894ed17ca089758b3a68fe3ca283f186ea941b69d51d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.",
                "category": "company",
                "datetime": 1784120477,
                "headline": "1 of Wall Street’s Favorite Stocks on Our Buy List and 2 We Brush Off"
              },
              {
                "id": 140907179,
                "url": "https://finnhub.io/api/news?id=340495186adc8c7a39222547fca20d68d8e33abc9353106904ef2fa4f9f6d435",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "A",
                "summary": "Agilent Technologies (A) shows a strong technical breakout setup with an 8/10 Technical Rating and 9/10 Setup Quality, combining a solid uptrend with a tight consolidation near a resistance zone for a potential energetic move.",
                "category": "company",
                "datetime": 1784113828,
                "headline": "Agilent Technologies (NYSE:A) Shows Strong Breakout Setup with Top-Tier Technical Ratings"
              },
              {
                "id": 140897052,
                "url": "https://finnhub.io/api/news?id=d3c01461e553edff92f6fa26c92fb12931f2973b5417e40b825effd9af455f29",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "SANTA CLARA, Calif., July 14, 2026--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb’s P",
                "category": "company",
                "datetime": 1784030400,
                "headline": "Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma"
              },
              {
                "id": 140897861,
                "url": "https://finnhub.io/api/news?id=7ed46f2519f301b40f26796faa434edf28b25ad1cb922969992a34846af05ea1",
                "image": "",
                "source": "Benzinga",
                "related": "A",
                "summary": "Approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who",
                "category": "company",
                "datetime": 1784016512,
                "headline": "Agilent Receives FDA Approval For The PD‑L1 LHC 28‑8 PharmDx Assay As Companion Diagnostic To Identify Patients With Carcinomas Who May Be Eligible For Treatment With OPDIVO or OPDIVO QVANTIG"
              },
              {
                "id": 140891351,
                "url": "https://finnhub.io/api/news?id=e241c1ffe64c739ef93aa279e16d8b927df3ed6bdc10741dd02d51309b8e4eef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "If you’re an Alamar Biosciences (ALMR) shareholder, Friday was a good day. The stock climbed +7.3%, closing the session at a new 52-week high of $28.42. That’s a tidy gain on a day when the S&P 500 barely nudged up +0.4% and some key industry peers actually lost ground.",
                "category": "company",
                "datetime": 1783975817,
                "headline": "Alamar Hits A High Note On Alzheimer's Buzz"
              },
              {
                "id": 140891435,
                "url": "https://finnhub.io/api/news?id=b2c25386d7c3ec7bdeefe1aa97da53868cf1b24991f81ccde9342c2c6f03d2f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Over the past six months, Agilent’s stock price fell to $134.31. Shareholders have lost 8.2% of their capital, which is disappointing considering the S&P 500 has climbed by 8.4%. This may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1783975599,
                "headline": "Agilent (A): Buy, Sell, or Hold Post Q1 Earnings?"
              },
              {
                "id": 140854874,
                "url": "https://finnhub.io/api/news?id=bff9ea6966cfd21f8e8d8baf218327bc3ed365657dbabb38f53b68db40ee60fc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "A enhances AI-powered lab software, automation and digital workflows to support drug discovery, biopharma research and long-term growth.",
                "category": "company",
                "datetime": 1783619580,
                "headline": "Agilent Strengthens Biopharma Growth Prospects With AI Expansion"
              },
              {
                "id": 140851723,
                "url": "https://finnhub.io/api/news?id=adab0e54b2cd05edff59575e88d1eecd33a73d0980c3a0ffdfab4fcc4e7eb226",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442797246/image_1442797246.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "A",
                "summary": "Illumina dominates genomics sequencing with recurring growth, NovaSeq X catalysts, and improving margins/FCF. Click to know why the ILMN shares look promising.",
                "category": "company",
                "datetime": 1783595255,
                "headline": "Illumina: While You Chased AI, This Healthcare Stock Built A $30B Moat"
              },
              {
                "id": 140841969,
                "url": "https://finnhub.io/api/news?id=929007abc6845945f0a033e193825ae16c6bff63e4c136fbb2550d41c7d31896",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Agilent Technologies, Inc. (NYSE:A) is one of the best healthcare stocks on our list. TheFly reported on July 6 that Evercore ISI analyst Vijay Kumar increased the firm’s price target on A to $148 from $144 while maintaining an Outperform rating […]",
                "category": "company",
                "datetime": 1783522222,
                "headline": "Is Agilent Technologies, Inc. (A) Stock Positioned for Growth as Life Sciences Sector Trends Stabilize?"
              },
              {
                "id": 140840661,
                "url": "https://finnhub.io/api/news?id=7474ad0e0ddf65f60b4ee001e92025316c8059b306b8c1ebe631753c931f1535",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "SANTA CLARA, Calif., July 08, 2026--Agilent Technologies Inc. (NYSE: A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.",
                "category": "company",
                "datetime": 1783512000,
                "headline": "Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis"
              },
              {
                "id": 140835525,
                "url": "https://finnhub.io/api/news?id=94b0899fa78390fbc58321c8109277f99f9fb5c37ef3cee2fd78ff7abbb2a8dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Agilent Technologies stock presents a clear valuation split right now, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while earnings-based market multiples imply the shares are already pricing in a lot of good news. Over the past 3 years, Agilent Technologies has returned 12.9%, which suggests the stock has rewarded patient holders but not in a way that obviously rules out further value questions. The recent launch of the AI powered xCELLigence RTCA...",
                "category": "company",
                "datetime": 1783455830,
                "headline": "Agilent (A) Stock Looks Below Fair Value On Cash Flow"
              },
              {
                "id": 140822551,
                "url": "https://finnhub.io/api/news?id=cee2ec535267e843a0b8f16ab25239634407c46036ba5069e90df7d6cd04facb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "Surplus Solutions LLC (\"Surplus Solutions\"), a portfolio company of NMS Capital (\"NMS\"), announced today the acquisition of DCM BioServices (\"DCM Bio\" or the \"Company\"), a Frederick, Maryland-based provider of laboratory automation maintenance, repair, technical support, and integration solutions. The acquisition expands Surplus Solutions' technical service capabilities and supports the Company's continued growth in the biotechnology, pharmaceutical, and life sciences sectors. Terms of the trans",
                "category": "company",
                "datetime": 1783358040,
                "headline": "Surplus Solutions, an NMS Capital Portfolio Company, Accelerates Technical Service Capabilities; Announces Partnership with DCM BioServices"
              },
              {
                "id": 140821772,
                "url": "https://finnhub.io/api/news?id=b03b0addb0d7acdbf47fda5c877fd3fee0fe08fe9b79b1b286111a4b4df934d5",
                "image": "",
                "source": "Benzinga",
                "related": "A",
                "summary": "Evercore ISI Group  analyst Vijay Kumar   maintains Agilent Technologies (NYSE:A) with a Outperform and raises the price target from $144 to $148.",
                "category": "company",
                "datetime": 1783336119,
                "headline": "Evercore ISI Group Maintains Outperform on Agilent Technologies, Raises Price Target to $148"
              },
              {
                "id": 140818525,
                "url": "https://finnhub.io/api/news?id=e8e67091f2f83771cb62d3ba1db83ca7b564b4ea75343756e5eddb52ce7632de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "A",
                "summary": "The global mobile mass spectrometers market is set to grow from USD 1.68 billion in 2026 to USD 2.87 billion by 2031, at a CAGR of 11.3%. This significant growth is driven by the demand for real-time, on-site chemical analysis in diverse industries such as environmental monitoring and defense. Ion sources top market components, with their pivotal role in sampling and analysis. Field-deployable platforms lead the product segment, offering portability essential for immediate results. North America",
                "category": "company",
                "datetime": 1783327440,
                "headline": "Mobile Mass Spectrometers Market by Application, Product Type & Component Global Forecast to 2031"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 46,
            "discarded_article_count": 35
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.5,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日5日)；站上MA50；升放量(近10日3日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 2308995.8,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 2161837.4,
              "avg_vol_20": 2210863.7,
              "avg_vol_30": 2308995.8,
              "range_pct_10": 0.1246065808297567,
              "range_pct_20": 0.1246065808297567,
              "range_pct_30": 0.1246065808297567,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9362673591697309,
              "dist_to_20d_high": 0.018396292655525743,
              "down_shrink_days": 5,
              "breakout_level_20d": 142.42,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 1
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.968025751072961,
              "turnoverUsdM": 178.972659,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.A",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 131.5014,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 5.9,
            "take_profit_price": 150.0488,
            "target_multiplier": 1.9,
            "technical_strength": 1.95,
            "take_profit_percent": 7.3
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2297736967681296,
          "stopLossPercent": 5.936051502145922,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.A",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 4.1493,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.97
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "強勢區",
      "score": 10,
      "value": 82.51
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0297
    },
    "kdj": {
      "d": 78.2,
      "j": 77.3,
      "k": 77.9,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 41.97
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 24777261,
      "recentSlope": 26846.1,
      "previousSlope": -226190
    },
    "rsi": 59.09,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 132.3528,
      "position": "SAR喺價下",
      "distancePct": 5.33,
      "previousTrend": "上升"
    },
    "ma50": 132.2014,
    "macd": {
      "macd": 2.4239457819303425,
      "trend": "強烈看漲",
      "signal": 2.1800439606309983,
      "histogram": 0.24390182129934423
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 134.9747,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 10
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.59,
      "score": 2,
      "avgVolume": 2174879,
      "currentVolume": 1280205
    },
    "derived": {
      "ma20": 135.505,
      "ma50": 132.2014,
      "prevClose": 138.37,
      "avgVolume10": 2042778,
      "avgVolume20": 2174879,
      "changePercent": 1.03,
      "avgVolumeForScore": 2174879
    },
    "ma_cross": {
      "ma20": 135.505,
      "ma50": 132.2014,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 135.045,
      "prevMa50": 131.681,
      "spreadPct": 2.5,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 128.5456,
      "upper": 142.4644,
      "position": "上半部"
    },
    "rsi_short": 58.87,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.59
    }
  }
}

{
  "close": 139.8,
  "volume": 1280205,
  "changePercent": 1.03
}